Bristol-Myers Squibb kidney transplant drug gets FDA nod
The drug demonstrated safety profile and positive results when investigated in open-label, randomized, multicenter, controlled Phase 3 studies comparing two dose regimens of Nulojix with another immunosuppressant cyclosporine.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.